Protagonist Therapeutics (PTGX) Cash from Operations (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Cash from Operations of 48943000.0 for Q1 2026, down 32.37% sequentially from 36975000.0 in Q4 2025, and down 139.04% YoY from 125363000.0 in Q1 2025.
Powered by 
Analysis
Protagonist Therapeutics (PTGX) Cash from Operations (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Cash from Operations for 12 years, with the latest figure at 48943000.0 in Q1 2026.
- Quarterly Cash from Operations fell 139.04% year-over-year to 48943000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 116635000.0 (down 134.62% YoY) and the FY2025 annual result came in at 57671000.0, down 68.68% from the prior year.
- Cash from Operations fell to 48943000.0 in Q1 2026 per PTGX's latest filing, from 36975000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 268622000.0 in Q2 2024 and troughed at 48943000.0 in Q1 2026.
- A 5-year average of 853352.94 and a median of 27429000.0 in 2024 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 1123.79% in 2024, down 272.04% in 2024.
- Over 5 years, Cash from Operations stood at 31635000.0 in 2022, then surged by 153.61% to 16960000.0 in 2023, then tumbled by 272.04% to 29178000.0 in 2024, then slipped by 26.72% to 36975000.0 in 2025, then sank by 32.37% to 48943000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 48943000.0, 36975000.0, and 1937000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Protagonist Therapeutics | 9.61 Bn | 9.61 Bn | - | 219.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 219.05 Mn |
| Mar 31, 2026 | -48.94 Mn |
| Dec 31, 2025 | -36.98 Mn |
| Sep 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Mar 31, 2025 | 125.36 Mn |
| Dec 31, 2024 | -29.18 Mn |
| Sep 30, 2024 | -27.86 Mn |
| Jun 30, 2024 | 268.62 Mn |
| Mar 31, 2024 | -27.43 Mn |
| Dec 31, 2023 | 16.96 Mn |
| Sep 30, 2023 | -26.61 Mn |
| Jun 30, 2023 | -26.24 Mn |
| Mar 31, 2023 | -34.35 Mn |
| Dec 31, 2022 | -31.64 Mn |
| Sep 30, 2022 | -25.20 Mn |
| Jun 30, 2022 | -13.64 Mn |
| Mar 31, 2022 | -37.67 Mn |
| Dec 31, 2021 | -26.94 Mn |
| Sep 30, 2021 | -28.47 Mn |